A bilateral aseptic pyogenic ventriculitis following a course of pembrolizumab, an anti-PD-1 immune checkpoint inhibitor treatment for metastatic small cell lung cancer
Published inThérapie, vol. 77, no. 6, p. 754-756
Publication date2022
First online date2022-05-11
Keywords
- Anticancer
- Clinical pharmacology
- Immunology
- Humans
- Small Cell Lung Carcinoma / drug therapy
- Immune Checkpoint Inhibitors / therapeutic use
- Cerebral Ventriculitis / drug therapy
- Lung Neoplasms / drug therapy
- Lung Neoplasms / pathology
Affiliation entities
Citation (ISO format)
TERRIER, Jean et al. A bilateral aseptic pyogenic ventriculitis following a course of pembrolizumab, an anti-PD-1 immune checkpoint inhibitor treatment for metastatic small cell lung cancer. In: Thérapie, 2022, vol. 77, n° 6, p. 754–756. doi: 10.1016/j.therap.2022.05.002
Main files (1)
Article (Published version)
Identifiers
- PID : unige:170982
- DOI : 10.1016/j.therap.2022.05.002
- PMID : 35660110
Additional URL for this publicationhttps://www.sciencedirect.com/science/article/pii/S0040595722000944
Journal ISSN0040-5957
